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PHeart Rhythm Disorders
re Transthoracic Echocardiographic
arameters Associated With
trial Fibrillation Recurrence or Stroke?
esults From the Atrial Fibrillation Follow-Up
nvestigation of Rhythm Management (AFFIRM) Study
rian Olshansky, MD,*. Eliot N. Heller, MD,† L. Brent Mitchell, MD,‡ Mary Chandler, MD,§
illiam Slater, MD, Martin Green, MD,¶ Michael Brodsky, MD# Patrick Barrell, BS,§
. Leon Greene, MD,§ and the AFFIRM Investigators
owa City, Iowa; Bronx and New York, New York; Calgary, Alberta, and Ottawa, Ontario, Canada;
eattle, Washington; and Irvine, California
OBJECTIVES The purpose of this study was to evaluate the associations of transthoracic echocardiographic
parameters with recurrent atrial fibrillation (AF) and/or stroke.
BACKGROUND The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study,
an evaluation of elderly patients with AF at risk for stroke, provided an opportunity to
evaluate the implications of echocardiographic parameters in patients with AF.
METHODS Transthoracic echocardiographic measures of mitral regurgitation (MR), left atrial (LA) diameter,
and left ventricular (LV) function were evaluated in the AFFIRM rate- and rhythm-control
patients who had sinus rhythm resume and had these data available. Risk for recurrent AF or
stroke was evaluated with respect to transthoracic echocardiographic measures.
RESULTS Of 2,474 patients studied, 457 had2/4 MR, and 726 had a LA diameter4.5 cm. The LV
ejection fraction was abnormal in 543 patients. The cumulative probabilities of at least one AF
recurrence/stroke were 46%/1% after 1 year and 84%/5% by the end of the trial
( 5 years), respectively. Multivariate analysis showed that randomization to the rhythm-control
arm (hazard ratio [HR] 0.64; p 0.0001) and a qualifying episode of AF being the first known
episode (HR 0.70; p 0.0001) were associated with decreased risk. Duration of qualifying AF
episode48 h (HR 1.55; p 0.0001) and LA diameter (p 0.008) were associated with an
increased risk of recurrent AF. Recurrent AF was more likely with larger LA diameters (HR 
1.21, 1.16, and 1.32 for mild, moderate, and severe enlargement, respectively). No transthoracic
echocardiographic measures were associated with risk of stroke.
CONCLUSIONS In the AFFIRM study, large transthoracic echocardiographic LA diameters were associated
with recurrent AF, but no measured echocardiographic parameter was associated with
stroke. (J Am Coll Cardiol 2005;45:2026–33) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.03.020Cardiology Foundation
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Ttrial fibrillation (AF) occurs most frequently in elderly
atients (1), who are at risk for recurrent AF if an episode
esolves or is cardioverted. Transthoracic echocardiographic
arameters, including left atrial (LA) diameter, left ventricular
LV) ejection fraction, and mitral regurgitation (MR), may be
ssociated with recurrent AF, stroke, or death (2–7).
The management of AF includes the prevention of throm-
oembolic events, slowing the ventricular response rate, and
he establishment, followed by maintenance, of sinus rhythm.
he Atrial Fibrillation Follow-Up Investigation of Rhythm
From the *University of Iowa, Iowa City, Iowa; †Bronx Lebanon Hospital Center,
ronx, New York; ‡Libin Cardiovascular Institute of Alberta, Calgary, Alberta,
anada; §Axio Research Corporation, Seattle, Washington; New York University
edical Center, New York, New York; ¶University of Ottawa, Ottawa, Ontario,
anada; and the #University of California Irvine, Irvine, California. Supported by the
ational Heart, Lung, and Blood Institute, Bethesda, Maryland, under contract
01-HC-55139. The AFFIRM Investigators and their affiliations are listed in
eference 17.a
Manuscript received November 23, 2004; revised manuscript received January 25,
005, accepted March 1, 2005.anagement (AFFIRM) study, a large, multicenter, random-
zed trial sponsored by the National Heart, Lung, and Blood
nstitute, compared rate- and rhythm-control approaches for
F patients at high risk for stroke or death. The primary end
oint was all-cause mortality (8–10).
The rate-control strategy included treatment designed to
revent thromboembolic events and to control the ventricular
esponse rate, but not to establish or maintain sinus rhythm.
he rhythm-control strategy included therapy designed to
aintain sinus rhythm and to prevent thromboembolic events.
he AFFIRM study offered the opportunity to evaluate
chocardiographic LA diameter, LV ejection fraction, and/or
R measures as predictors of AF recurrence or stroke in
atients with AF at high risk for stroke or death.
ETHODS
he AFFIRM study design, detailed elsewhere (8), was
pproved by the AFFIRM Steering Committee, by the
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June 21, 2005:2026–33 Echocardiographic Parameters in the AFFIRM Studynstitutional Review Board of the University of Washington
for the Clinical Trial Center), by the Data and Safety
onitoring Board, and by each participating site’s local
nstitutional review board. All patients gave informed,
ritten consent to participate in the trial. The AFFIRM
tudy indicated that the rhythm-control strategy offered no
urvival benefit (10).
This substudy considered all AFFIRM study patients in
he rate- and rhythm-control arms in whom: 1) restoration
f sinus rhythm was documented within two months of
andomization, either spontaneously or with electrical
nd/or chemical cardioversion, and 2) a transthoracic echo-
ardiogram was reported. We evaluated the association of
pecific echocardiographic parameters with AF recurrence
nd stroke (7,9,10).
Recurrent AF was identified on an electrocardiogram
ECG) or rhythm strip after the qualifying episode of AF
ad stopped spontaneously or was converted electrically
nd/or pharmacologically to sinus rhythm. Twelve-lead
CGs were obtained at 4 and 12 months after randomiza-
ion, and a rhythm strip was obtained at each 4-month visit.
he ECGs or rhythm strips were also recorded at any time
hat symptoms suggested AF recurrence. The time between
estoration of sinus rhythm and AF recurrence was ana-
yzed.
Stroke was defined as a focal neurologic deficit of any
everity lasting 24 h. All strokes were adjudicated by a
troke Events Committee composed of neurologists
linded to the treatment assignment.
reatment during follow-up. Patients assigned to the
hythm-control strategy in the AFFIRM study were pre-
cribed antiarrhythmic drugs commonly used to establish
nd/or maintain sinus rhythm. Patients assigned to the
ate-control strategy received digoxin, non-dihydropyridine
alcium antagonists, and/or beta-blockers (10). The treating
hysician prescribed rhythm- and rate-control drugs based
n prespecified guidelines (7,9–11). Adequacy of rhythm-
nd rate-control was determined by history, physical exam-
nation, and an ECG rhythm strip performed at least at
ach four-month visit. Rate- and rhythm-control drugs
ere adjusted as necessary. Cardioversion was performed as
eeded in the rhythm-control group. If adequate rhythm or
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
AF  atrial fibrillation
AFFIRM  Atrial Fibrillation Follow-Up Investigation
of Rhythm Management
CAD  coronary artery disease
CHF  congestive heart failure
ECG  electrocardiogram
LA  left atrial/atrium
LV  left ventricular/ventricle
MR  mitral regurgitationate control could not be achieved with at least two iedications given separately, the treating physician could
roceed with an innovative therapy (7).
chocardiographic procedures. Patients were included in
his study if they had a transthoracic two-dimensional and
-mode echocardiogram (with Doppler measurements to
ssess MR). The test was performed with various types and
odels of equipment and by various cardiac sonographers at
13 clinical sites, according to local practice. Echocardio-
rams performed within 12 months of qualifying AF
pisodes were reported and interpreted locally. The echo-
ardiogram was performed within 30 days in 1,557 (63%)
atients, between 31 and 59 days in 267 (11%) patients,
etween 60 and 89 days in 170 (7%) patients, and at 90
ays in 479 (19%) patients. Measurements collected were
A diameter, LV ejection fraction, and qualitative assess-
ent of MR. Transesophageal echocardiography data were
ot recorded for purposes of this trial.
ata collection. Baseline clinical data were tabulated.
ollow-up data related to AF recurrence and stroke was
ollected at two months and at four-month intervals
hereafter.
tatistics. The LA size was analyzed both as a dichoto-
ous variable (4.5 cm vs. 4.5 cm) and as a categorical
ariable (4.1 cm, 4.1 to 4.5 cm, 4.6 to 5.5 cm, or 5.5
m). Mitral regurgitation was analyzed as a dichotomous
ariable (2/4 vs. 2). The LV ejection fraction,
nalyzed as a categorical variable, was divided into normal
50%), mild dysfunction (40% to 49%), moderate dys-
unction (30% to 39%) and severe dysfunction (30%).
Means and standard deviations were calculated for con-
inuous variables. Frequencies and percentages were calcu-
ated for categorical variables. Continuous variables were
nalyzed using t tests. Categorical variables were analyzed
sing chi-square tests for homogeneity.
Cumulative survival probabilities were calculated by the
aplan-Meier method. Survival distributions were com-
ared using log-rank statistics.
Cox proportional hazards models were used for multivar-
ate analyses of time to recurrent AF and time to stroke. An
nitial stepwise analysis was used to select significant demo-
raphic variables (age, gender, qualifying episode as first AF
pisode, duration of qualifying episode 48 h, history of:
oronary artery disease [CAD], congestive heart failure
CHF], hypertension, diabetes, smoking, stroke, and myo-
ardial infarction, and New York Heart Association func-
ional class at baseline). A full model containing the
emographic variables that were selected in the stepwise
nalysis, plus treatment arm and the echocardiographic
ariables (LA size, MR 2 and LV ejection fraction) was
un. A second stepwise model was used to select the
ignificant echocardiographic variables after controlling for
ignificant demographic variables and treatment arm. Those
ariables found significant in this stepwise model were
ncluded in the final, reduced model. Significance was
ndicated by a p value 0.05.
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Echocardiographic Parameters in the AFFIRM Study June 21, 2005:2026–33ESULTS
he AFFIRM study enrolled 4,060 patients; 2,033 were
andomized to the rhythm-control arm and 2,027 to the
ate-control arm. A transthoracic echocardiogram was per-
ormed and reported for 3,311 patients (82%). Sinus rhythm
esumed in 3,043 patients by the two-month visit; 2,474
81%) of these patients had an echocardiogram reported and
re the subjects of this analysis (Table 1). The mean time
etween the echocardiogram and the date of qualifying
pisode of AF was 49  110 days.
Among patients who did not have sinus rhythm by the
-month visit, a high proportion (70%) had been random-
zed to the rate-control arm of AFFIRM study and/or had
xperienced a qualifying episode of AF lasting 48 h.
therwise, baseline characteristics of patients included in
his analysis were similar to those who had echocardiograms
ut remained in AF and those who did not have an
chocardiogram (Table 1).
Of the 2,474 patients in this analysis, 457 of 2,426 (19%)
ad 2/4 MR, 264 of 1,918 (14%) had LV diastolic size
5.7 cm, 306 of 1,696 (18%) had LV systolic size4.0 cm,
43 of 2,255 (24%) had an LV ejection fraction 0.50, and
26 of 2,334 (31%) had an LA diameter 4.5 cm.
In the rhythm-control arm, amiodarone was the first
ntiarrhythmic drug prescribed in 448 patients (36%).
ther antiarrhythmic drugs used initially were sotalol (438
atients, 35%), propafenone (127 patients, 10%), quinidine
69 patients, 6%), flecainide (65 patients, 5%), procainamide
68 patients, 5%), disopyramide (29 patients, 2%), and
able 1. Baseline Characteristics of the Population Analyzed Ver
Total
Had
umber 4,060
ge (yrs) 69.7  9.0
ale 2,466 (61)
ate-control arm 2,027 (50)
rimary diagnosis
CAD 1,059 (26)
CM 194 (5)
HTN 2,063 (51)
Other 240 (6)
None 504 (12)
ther diagnosis
Diabetes 813 (20)
Pulmonary disease 591 (15)
Prior stroke or TIA 542 (13)
istory
CHF 939 (23)
Angina 1,047 (26)
MI 705 (17)
ualifying AF duration
48 h 1,251 (31)
48 h 2,808 (69)
irst episode of AF 1,391 (36)
rior drug failures 713 (18)
F episodes more than once per week 676 (26)
umbers in parentheses are percents. *Patients who were in sinus rhythm at random
AF  atrial fibrillation; CAD  coronary artery disease; CHF  congestive heart failur
transient ischemic attack.oricizine (10 patients, 0.8%). Of those taking an antiar-
hythmic drug other than amiodarone as the first drug, 312
f 837 (37%) were prescribed amiodarone later.
In the rate-control arm, 504 patients (52%) were pre-
cribed a beta-blocker and 491 patients (61%) were pre-
cribed a calcium-channel blocker as the first rate-
ontrolling drug (some received both). Overall, 361 (38%)
ere prescribed an angiotensin-converting enzyme (ACE)
nhibitor.
ssociations with LA diameter. Among the 2,334 pa-
ients who had their LA diameter documented, the mean
ollow-up time was 1,298  460 days (range, 0 to 2,167
ays). Of these, 999 were in the rate-control arm and 1,335
ere in the rhythm-control arm (Table 2).
Patients with an enlarged LA (4.5 cm) had significantly
arger LV diameters, were more likely to be male, and were
ore likely to have CHF, angina, myocardial infarction,
nd an abnormal LV ejection fraction than patients with a
maller LA. In patients with an enlarged LA, the AF
pisode serving as the qualifying episode for the AFFIRM
tudy was more likely to persist 48 h. Primary diagnoses
iffered in patients with and without an enlarged LA. A
arger proportion of patients with an enlarged LA had a
rimary diagnosis of CAD or cardiomyopathy. Thirty-three
ercent with LA  4.5 cm were prescribed an ACE
nhibitor, versus 49% with LA  4.5 cm (p  0.0001).
Patients with large LA diameters were more likely to be
rescribed amiodarone as the first antiarrhythmic drug (34%
ith LA 4.5 cm vs. 40% with LA 4.5 cm; p  0.03).
ther AFFIRM Patients
o and Achieved
s Rhythm*
Had Echo, Did Not
Achieve Sinus Rhythm* No Echo
2,474 837 749
.5  8.9 69.9  9.3 70.4  8.8
,469 (59) 540 (65) 457 (61)
,063 (43) 587 (70) 377 (50)
626 (25) 189 (23) 244 (33)
111 (4) 59 (7) 24 (3)
,285 (52) 438 (52) 340 (45)
147 (6) 60 (7) 33 (4)
305 (12) 91 (11) 108 (14)
491 (20) 165 (20) 157 (21)
362 (15) 110 (13) 119 (16)
364 (15) 92 (11) 86 (11)
561 (23) 232 (28) 146 (19)
632 (26) 191 (23) 224 (30)
428 (17) 129 (15) 148 (20)
915 (37) 81 (10) 255 (34)
,559 (63) 756 (90) 493 (66)
933 (39) 277 (34) 181 (25)
384 (16) 155 (19) 174 (23)
362 (24) 164 (30) 150 (27)
n, the baseline visit, or the 2-month visit.sus O
Ech
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June 21, 2005:2026–33 Echocardiographic Parameters in the AFFIRM Studyatients with MR were more likely to be prescribed amio-
arone and ACE inhibitors as first drugs.
ecurrent AF. The AF recurred in 1,128 patients in the
rst year and in 1,686 patients by the end of the trial. The
aplan-Meier estimates of the probabilities of AF recur-
ence were 46% after one year and 84% at the end of the
rial. The risk of recurrent AF did not differ between those
ho had an echocardiogram performed and those who did
ot.
In a multivariate model of time to recurrent AF after
stablishment of sinus rhythm, having a first episode of AF
s the qualifying episode and being randomized to the
hythm-control arm of the AFFIRM study were associated
ith a decreased risk of recurrent AF, whereas a qualifying
pisode lasting 48 h was associated with an increased risk
f recurrent AF. After controlling for these variables, LA
iameter was associated with recurrent AF (Table 3), with
arger LA diameters associated with increased risk of recur-
ent AF compared with patients with normal LA diameters
Fig. 1).
ccurrence of stroke. Stroke occurred in 29 patients in
able 2. Baseline Characteristics, Left Atrium Size
Total
umber (%) 2,334
ge (yrs) 69.5  8.9
ale 1,368 (59)
ate-control arm 999 (43)
rimary diagnosis
CAD 575 (25)
CM 102 (4)
HTN 1,219 (52)
Other 143 (6)
None 295 (13)
ther diagnosis
Diabetes 462 (20)
Pulmonary disease 331 (14)
Prior stroke or TIA 340 (15)
istory
CHF 518 (22)
Angina 585 (25)
MI 399 (17)
ualifying AF duration
48 h 860 (37)
48 h 1,474 (63)
irst episode of AF 883 (39)
rior drug failures 364 (16)
F episodes more than once per week 343 (24)
eart rate at baseline 70.0  15.4
itral regurgitation 2/4 439 (19)
VEF*
Normal 1,631 (70)
Mild dysfunction 259 (11)
Moderate dysfunction 148 (6)
Severe dysfunction 96 (4)
Unknown 200 (9)
V systolic diameter 3.3  0.9
V diastolic diameter 5.0  0.7
ome data represent mean  SD. *Normal LVEF  0.50; mild dysfunction  0.
LA  left atrium; LV  left ventricular; LVEF  left ventricular ejection fractihe first year and in 86 patients by the end of the trial. The waplan-Meier estimates of the probability of stroke were 1%
fter one year and 5% at the end of the trial. The risk of
troke in patients who had an echocardiogram performed
as not significantly different from that in patients who did
ot have an echocardiogram performed.
In a multivariate model of time to occurrence of stroke,
emale gender, history of stroke, history of myocardial
nfarction, and a qualifying episode lasting 48 h were
ssociated with increased follow-up risk of stroke. After
ontrolling for these variables, no transthoracic echocardio-
raphic variables studied were associated with the risk of
troke (Table 4). Although MR 2 was of borderline
ignificance in a model that included significant demo-
raphic variables plus all echocardiographic variables, when
stepwise selection model was run, neither MR nor any of
he other echocardiographic parameters met the selection
riterion of p  0.05.
ISCUSSION
his AFFIRM substudy evaluated patients with AF treated
A Size <4.5 cm LA Size >4.5 cm p Value
1,608 (69) 726 (31)
69.6  8.8 69.3  9.1 0.58
878 (55) 490 (67) 0.0001
698 (43) 301 (41) 0.38
348 (22) 227 (31) 0.0001
50 (3) 52 (7)
888 (55) 331 (46)
79 (5) 64 (9)
243 (15) 52 (7)
301 (19) 161 (22) 0.05
225 (14) 106 (15) 0.70
234 (15) 106 (15) 0.98
282 (18) 236 (33) 0.0001
373 (23) 212 (29) 0.002
237 (15) 162 (22) 0.0001
695 (43) 165 (23) 0.0001
913 (57) 561 (77)
577 (37) 306 (43) 0.008
261 (16) 103 (14) 0.21
244 (24) 99 (24) 0.96
70.5  15.1 71.3  16.1 0.25
209 (13) 230 (32) 0.0001
1,195 (74) 436 (60) 0.0001
153 (10) 106 (15)
79 (5) 69 (10)
43 (3) 53 (7)
138 (9) 62 (9)
3.2  0.8 3.6  1.0 0.0001
4.8  0.7 5.2  0.8 0.0001
49; moderate dysfunction  0.30–0.39; severe dysfunction  0.30.
er abbreviations as in Table 1.Lith a rate- or a rhythm-control approach. It evaluated the
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Echocardiographic Parameters in the AFFIRM Study June 21, 2005:2026–33ssociation of frequently measured transthoracic echocardio-
raphic parameters with AF recurrence and stroke. The
ollow-up probability of at least one episode of AF recurrence
as high, even in the patients randomized to the rhythm-
ontrol arm (10,11). The LA diameter was associated with
ecurrent AF in the rate- and rhythm-control groups, but MR
nd depressed LV ejection fraction were not. No transthoracic
chocardiographic parameter predicted stroke.
chocardiographic predictors of AF recurrence. The ini-
ial occurrence of AF has been associated with LA enlarge-
ent, as determined by roentgenography (12), autopsy (13),
able 3. Relative Risk of Recurrence of Atrial Fibrillation
HR
hythm arm 0.65
ualifying episode of atrial fibrillation is the first episode 0.70
uration of qualifying episode 48 h 1.52
eft atrial size
4.1 cm 1.00
4.1–4.5 cm 1.23
4.6–5.5 cm 1.16
5.5 cm 1.33
itral regurgitation 2/4 1.07
educed ejection fraction 0.97
Full model includes those demographic variables selected in a stepwise model plus all
hose echocardiographic variables selected in a stepwise selection model.
CI  confidence interval; HR  hazard ratio.
igure 1. Recurrence of atrial fibrillation (Afib) and left atrial diameter. N
f patients experiencing atrial fibrillation recurrence by this time point; %  Ka
ime point.r angiography (14). Small patient cohorts suggest that
chocardiographic measurements of LA diameter correlate
ith the probability of maintaining sinus rhythm after
pontaneous, chemical, or direct current cardioversion of
F. This association has been supported by some (4,15–21)
ut not all (22–25) studies.
The LA volume measured by transthoracic echocardiog-
aphy may be superior to LA diameter for predicting adverse
utcomes, including recurrent AF. Perhaps LA volume
ould be a more robust predictor of AF recurrence than LA
iameter used here.
ull Model* Reduced Model
95% CI p HR 95% CI p
.58–0.72 0.0001 0.64 0.58–0.71 0.0001
.62–0.78 0.0001 0.70 0.63–0.78 0.0001
.35–1.72 0.0001 1.55 1.39–1.74 0.0001
0.01 1.00 0.008
1.21
1.16
1.32
.93–1.23 0.32
.90–1.04 0.39
ardiographic variables. Reduced model includes the same demographic variables plus
ber of patients available for evaluation at this time point; events numberF
0
0
1
0
0
echocnum
plan-Meier estimate of cumulative atrial fibrillation recurrence rate at this
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June 21, 2005:2026–33 Echocardiographic Parameters in the AFFIRM StudyPrevious reports showed an association between LA size
nd AF recurrence rates. Flaker et al. (26) performed a
ultivariate analysis on potential clinical and transthoracic
chocardiographic predictors of AF recurrence in 341 pa-
ients in the Stroke Prevention in Atrial Fibrillation
SPAF)-I and -II trials. Recurrent AF was predicted by
dvancing age, presence of CHF, prior myocardial infarc-
ion, and LA diameter. Similarly, Alt et al. (27) performed
multivariate analysis on potential clinical and echocardio-
raphic predictors of AF recurrence in 187 patients treated
ith sotalol after direct-current cardioversion of AF. Re-
urrent AF was predicted by advancing age, presence of
oronary artery disease, prolonged (2 months) index
pisode of AF, and LA diameter 6.0 cm. Notably, these
nalyses were performed on populations for which a limited
umber of co-variables could be assessed.
The primary analysis of this study involved 2,474 pa-
ients, a large population permitting a more inclusive
ultivariate analysis that confirmed an independent associ-
tion of LA diameter with AF recurrence. The present
tudy is more contemporary and includes a large patient
opulation receiving antiarrhythmic drug therapy with fre-
uent use of amiodarone. In contrast, it is noteworthy that
wo univariate analyses not reporting an association between
A diameter and AF recurrence were of patients receiving
miodarone therapy. However, these prior studies may have
sed amiodarone for refractory cases, unlike the treatment
pproach in the AFFIRM study (22,23).
Other potential transthoracic echocardiographic predic-
ors of AF recurrence have been studied less extensively.
he LV end-diastolic dimension has been suggested as a
redictor of recurrent AF in one study (17), but not another
25). Fractional shortening did not predict recurrent AF in
wo studies (4,25), nor did LV wall thickness (25). We
ound no association between LV systolic function as
easured by the ejection fraction and the follow-up prob-
able 4. Relative Risk of Stroke
Full M
HR 95%
hythm arm 0.86 0.53–
istory of stroke 1.96 1.11–
istory of myocardial infarction 1.97 1.10–
emale gender 1.25 0.76–
uration of qualifying episode 48 h 1.29 0.76–
eft atrial size
4.1 cm 1.00
4.1–4.5 cm 1.55
4.6–5.5 cm 1.12
5.5 cm 0.80
itral regurgitation 2/4 1.83 1.04–
educed ejection fraction 0.81 0.57–
Full model includes those demographic variables selected in a stepwise model plus all
hose echocardiographic variables selected in a stepwise selection model.
Abbreviations as in Table 3.bility of recurrent AF. achocardiographic predictors of thromboembolic
vents. Echocardiographic parameters have been evaluated
s predictors of thromboembolic events, particularly throm-
oembolic stroke in follow-up. The most frequently studied
chocardiographic parameter has been the LA diameter.
ome studies have reported a statistically significant associ-
tion between LA diameter and thromboembolic events
28,29); others have not (30–32). Multivariate analyses
ikewise yielded conflicting results (33–37).
Other transthoracic echocardiographic parameters have
een evaluated in patients with AF in relation to thrombo-
mbolic events. Some univariate associations have been
bserved between thromboembolic events and LV end-
iastolic diameter (38), LV end-systolic diameter (38),
ractional shortening (38), and LV wall thickness or ven-
ricular mass (29,38,39). Other univariate analyses have
ound no associations between thromboembolic events and
V end-diastolic diameter (30,35), LV end-systolic diam-
ter (35), fractional shortening (29,37), or LV wall thickness
r ventricular mass (30,35,37). None of these associations
ave been supported in multivariate analyses (33–37), with
he exception of LV mass in one study (39) and qualitative
ssessment of global LV systolic dysfunction in another
38).
In the present study, neither LA diameter nor any other
tudied transthoracic echocardiographic parameter was as-
ociated with thromboembolic events in univariate or mul-
ivariate analyses. Transesophageal echocardiographic data
e.g., appendage velocities, appendage thrombus, and
moke), not recorded or assessed in this study, may have
rovided better predictive measures of stroke risk.
R. Mitral regurgitation and AF often coexist. In fact,
57 of 2,426 (19%) of the AFFIRM study patients had
chocardiographic evidence of 2/4 MR. Mitral regur-
itation can cause atrial stretch and LA enlargement, either
f which may change atrial electrophysiologic properties and
Reduced Model
p HR 95% CI p
0.56 0.91 0.59–1.39 0.65
0.02 1.82 1.10–3.01 0.02
0.02 1.65 1.00–2.71 0.05
0.38 1.65 1.07–2.54 0.02
0.35 1.69 1.05–2.72 0.03
0.44
0.04
0.25
ardiographic variables. Reduced model includes the same demographic variables plusodel*
CI
1.41
3.46
3.51
2.08
2.21
3.23
1.16
echoclter atrial anatomy. Accordingly, MR may facilitate the
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ntiarrhythmic drug therapy.
The effect of the MR jet to lessen LA stasis may protect
he LA from developing thrombi, whether or not the
atient is taking an anticoagulant (40,41). Previous studies
valuating the relationship between MR and thromboem-
olic events (or their surrogates of LA thrombus or LA
pontaneous echo contrast) provide conflicting results, but
any of these studies involve patients with rheumatic mitral
alve disease, and these data do not pertain to this patient
opulation. Studies associating MR with a lower risk of
hromboembolic events or stroke in patients with nonrheu-
atic AF reported disparate results. Some support a rela-
ionship (40,42), and some dispute it (31,32,38). In the
resent study not restricted to subjects with rheumatic heart
isease, no statistically significant association was found
etween MR determined by the transthoracic echocardio-
ram and the follow-up probability of recurrent AF or
hromboembolic stroke.
tudy limitations. Patients randomized into the AFFIRM
tudy had to be candidates for a therapeutic approach that
ttempted to establish and maintain sinus rhythm. Possibly,
atients with exceedingly large LA diameters and those
ith severe MR were not included in the AFFIRM study
ecause of the bias that they may not maintain sinus
hythm. The LA diameter was not corrected for body
urface area. Those with larger LA diameters were more
ikely to be men, were sicker and, therefore, were less likely
o maintain sinus rhythm. Patients with severe MR who
ere going to undergo valvular replacement or repair would
ot have been included in this study. Accordingly, this study
ould have been biased toward a less strong association
etween LA diameter and/or MR and the probabilities of
ecurrent AF and stroke. Also, AF may have recurred, been
ransient, or gone unrecognized. Given the large numbers of
atients observed, it is likely that even if some recurrences
ere missed, the comparison between subgroups provided
ccurate differences in recurrence rates.
Entry criteria into the AFFIRM study did not require a
ransthoracic echocardiogram. Accordingly, not all patients
ad one performed, and those that did may have had an
chocardiogram performed at a time other than at randomiza-
ion. Those patients who had an echocardiogram performed
iffered slightly from patients who did not. Inclusion of only
atients who had a transthoracic echocardiogram performed
ay incur study bias and impact the results.
Temporal changes in echocardiographic parameters for
ndividual patients cannot be identified by a single echocar-
iogram. This analysis was limited to evaluation of widely
easured and reported but locally performed and locally
nterpreted transthoracic echocardiographic parameters. Al-
hough this assessment represents the mainstream of echo-
ardiographic practice, it is possible that if all transthoracic
chocardiograms had been performed and/or interpreted at
ne site, results may have differed. It is also possible that
imilar parameters measured by transesophageal echocardi-
1graphy may have provided different results or that other
ransthoracic echocardiographic or transesophageal echo-
ardiographic parameters are associated with AF recurrence
r stroke.
The incomplete nature of the AFFIRM study drug
atabase complicates analysis. Patients could be and were
witched from one antiarrhythmic drug to another and
laced on and off warfarin. Although data regarding drug
se were tabulated at each follow-up visit, the frequency and
he dosage were not recorded. There was no way to
istinguish whether the drug was taken for a few dosages or
ver the entire interval between follow-up visits.
Finally, the low stroke rate observed in this study may
imit the power of an analysis to associate echocardiographic
arameters with stroke.
ONCLUSIONS
or patients in the AFFIRM study who resumed sinus
hythm after an episode of AF, recurrent AF was associated
ith echocardiographic measurement of the LA diameter.
he MR and LV ejection fraction, as measured by a
tandard transthoracic echocardiogram, were not associated
ith recurrent AF. No transthoracic echocardiographic
arameter evaluated was associated with stroke occurrence.
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